Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-label Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

NCT05765812 is registered in ClinicalTrials.gov with Debiopharm International SA as lead sponsor.

NCT NCT05765812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05765812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-label Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Lead sponsor
Debiopharm International SA
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 15, 2023
Completion date
September 30, 2028
Enrollment
116 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, grade iii, glioblastoma idh (isocitrate dehydrogenase) wildtype